View Older Stories View More Recent Stories

Apr 30, 2021 06:45PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 30, 2021 04:05PM Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
Apr 28, 2021 08:30AM Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
Apr 26, 2021 04:05PM Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
Mar 23, 2021 08:30AM Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
Mar 18, 2021 04:33PM Sarepta Therapeutics (SRPT) Announces Limb-Girdle Muscular Dystrophy Treatement SRP-9003 Shows Sustained Expression and Functional Improvements 2 Years After Administration
Mar 18, 2021 04:31PM Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administr
Mar 15, 2021 08:30AM Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
Mar 1, 2021 04:05PM Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
Feb 26, 2021 07:12PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 25, 2021 02:10PM Sarepta Therapeutics (SRPT) Announces FDA Approval of AMONDYS 45 (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophyin Patients Amenable to Skipping Exon 45
Feb 25, 2021 02:10PM Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
Feb 24, 2021 04:30PM Sarepta Therapeutics to Present at Upcoming Investor Conferences
Feb 22, 2021 08:30AM Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
Feb 4, 2021 04:30PM Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
Jan 29, 2021 08:30PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 13, 2021 08:30AM Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
Jan 8, 2021 08:30AM Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Jan 7, 2021 04:09PM Sarepta Therapeutics (SRPT) Says Part 1 of Study SRP-9001-102 Met Primary Endpoint, But Did Not Achieve Statistical Significance in NSAA Total Score Improvement
Jan 7, 2021 04:05PM Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Dec 31, 2020 06:30PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 14, 2020 08:30AM Sarepta Therapeutics Announces Executive Management Changes
Dec 7, 2020 08:56AM Sarepta Therapeutics (SRPT) Announces Positive Clinical Results from MOMENTUM, Phase 2 Clinical Trial of SRP-5051 in Patients with DMD Amenable to Skipping Exon 51
Dec 7, 2020 08:55AM Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Dec 4, 2020 04:05PM Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
Nov 30, 2020 06:05PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 25, 2020 08:30AM Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
Nov 20, 2020 08:30AM Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
Nov 5, 2020 04:05PM Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
Nov 5, 2020 04:02PM Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
Nov 2, 2020 04:30PM Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
Oct 30, 2020 07:16PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 29, 2020 08:36AM Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
Oct 22, 2020 07:30AM Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
Sep 30, 2020 06:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 28, 2020 08:56AM Sarepta Therapeutics (SRPT) Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for DMD
Sep 28, 2020 08:56AM Sarepta Therapeutics (SRPT) Investigational Gene Therapy SRP-9003 for LGMD2E Shows Sustained Functional Improvements 18-months After Administration
Sep 28, 2020 08:55AM Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration
Sep 28, 2020 08:55AM Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Sep 15, 2020 08:30AM Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
Sep 14, 2020 08:32AM Sarepta Therapeutics (SRPT) announces L-T functional data from its Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society
Sep 14, 2020 08:30AM Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society
Sep 9, 2020 05:20PM Sarepta Therapeutics (SRPT) has completed Type C meeting with OTAT to obtain concurrence on commencement of its next clinical trial for SRP-9001
Sep 9, 2020 05:19PM Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Sep 3, 2020 04:30PM Sarepta Therapeutics to Present at Upcoming Investor Conferences
Aug 31, 2020 06:30PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 25, 2020 08:47AM Sarepta Therapeutics (SRPT) Said FDA Accepted Casimersen (SRP-4045) NDA for Duchenne Muscular Dystrophy, Granted Priority Review Status
Aug 25, 2020 08:45AM Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
Aug 11, 2020 08:32AM Sarepta Therapeutics (SRPT), University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases
Aug 11, 2020 08:30AM Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases
View More Recent Stories View Older Stories